Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration raised no objections to proposed protocol amendments for the ongoing Phase 2 HARMONIC trial evaluating LP-300 in never-smokers with advanced non-small cell lung cancer adenocarcinoma. The company said the FDA's written response to its Type C meeting request provides a clearer regulatory path forward for the program, including a strategy focused on the EGFR exon 21 L858R-mutant never-smoker population, where emerging data suggest LP-300 may offer differentiated benefit in combination with standard chemotherapy following kinase inhibitor treatment failure.
The FDA's support for the amendments marks a critical milestone for Lantern Pharma, as it validates the company's precision oncology approach using its proprietary RADR platform to identify patient subgroups most likely to benefit from LP-300. The HARMONIC trial is evaluating LP-300 in combination with standard chemotherapy (cisplatin/pemetrexed) in never-smoker patients with relapsed advanced lung adenocarcinoma after tyrosine kinase inhibitor (TKI) treatment. By narrowing the focus to the EGFR exon 21 L858R mutation subgroup, the company aims to enhance the probability of success and expedite the development timeline.
The implications of this FDA feedback are significant for Lantern Pharma and the broader lung cancer community. Never-smokers with non-small cell lung cancer represent a distinct patient population with unique molecular characteristics, and current treatment options after TKI failure are limited. LP-300, a cisplatin/ethacraplatin analog, is designed to overcome resistance mechanisms and has shown promising preclinical activity in this niche.
Lantern Pharma's clinical pipeline also includes LP-184 (acylfulvene) and LP-284, a TC-NER targeting compound for hematologic and solid tumors. Additionally, through its wholly owned CNS-focused subsidiary Starlight Therapeutics, LP-184 is being developed for pediatric CNS cancers. The company's RADR platform and its recently launched multi-agentic AI co-scientist platform, withZeta.ai, which is now commercially available as a subscription-based research platform, represent a new revenue stream for the company.
The FDA's no-objection letter allows Lantern Pharma to proceed with the amended trial protocol without additional regulatory hurdles, potentially accelerating patient enrollment and data collection. The company operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas. For more information, visit the company's newsroom at https://ibn.fm/LTRN.
